A recent review found that new methods of treatment for prurigo nodularis had promising results, including approaches that target interleukin 31 and its receptor. A review published in Dermatology and ...
Please provide your email address to receive an email when new articles are posted on . By week 12, itch and pain scores decreased 78.3% and 53.7% in the prurigo nodular and chronic pruritus of ...
Prurigo nodularis (PN) is extremely itchy skin that leads to a bumpy rash. The rash appears as the result of repeated scratching, picking, or rubbing of the itchy areas of the skin. There isn’t one ...
The FDA approved the interleukin (IL)-31 monoclonal antibody nemolizumab (Nemluvio) for treating prurigo nodularis, drugmaker Galderma announced on Tuesday. The approval stipulates use in adults with ...
Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...
Demonstrates Long-Term Disease Control In Prurigo Nodularis Up To Three Years - AETOS....(BUSINESS WIRE )--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study inv ...
The FDA has approved dupilumab (Dupixent) as the first treatment with an indication for prurigo nodularis, Sanofi and Regeneron announced. A chronic inflammatory skin condition affecting about 75,000 ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25 th World Congress of Dermatology (WCD) in Singapore. The results highlight ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...
Please provide your email address to receive an email when new articles are posted on . By week 100, 90% of participants achieved a 4-point or higher improvement in itch and 70% experienced an ...
Dupixent, an interleukin-4 receptor alpha antagonist, is the first treatment indicated for prurigo nodularis. Credit: Getty Images. The Food and Drug Administration (FDA) has approved Dupixent ® ...
The first and only treatment for the disabling skin condition prurigo nodularis has been approved by the Food and Drug Administration in a development a D.C. dermatologist calls “huge.” Prurigo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results